Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reference drug pricing.

Literature DB >> 12160115

Reference drug pricing.

Sebastian Schneeweiss, Stephen B Soumerai, Malcolm Maclure.

Abstract

Mesh：

Substances：

Year: 2002 PMID： 12160115 PMCID： PMC117083

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

5 in total

1. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.

Authors: Aslam Anis
Journal: CMAJ Date: 2002-03-19 Impact factor: 8.262

Review 2. The case for a medicare drug coverage benefit: a critical review of the empirical evidence.

Authors: A S Adams; S B Soumerai; D Ross-Degnan
Journal: Annu Rev Public Health Date: 2001 Impact factor: 21.981

3. Prescription duration after drug copay changes in older people: methodological aspects.

Authors: Sebastian Schneeweiss; Malcolm Maclure; Stephen B Soumerai
Journal: J Am Geriatr Soc Date: 2002-03 Impact factor: 5.562

4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Authors: Sebastian Schneeweiss; Stephen B Soumerai; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Alexander M Walker
Journal: CMAJ Date: 2002-03-19 Impact factor: 8.262

5. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Authors: Sebastian Schneeweiss; Alexander M Walker; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Stephen B Soumerai
Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245

5 in total

3 in total

Reference drug pricing.

1. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.

Review 2. The case for a medicare drug coverage benefit: a critical review of the empirical evidence.

3. Prescription duration after drug copay changes in older people: methodological aspects.

4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

5. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

1. Pharmaceutical cost containment with reference-based pricing: time for refinements.

2. Reference drug programs: effectiveness and policy implications.

3. Reference pricing system and competition: case study from Portugal.